Sunstone announce new corporate structure and brand names
Copenhagen, 21 February 2019
SunstoneCapital today announce that the two investment arms of Sunstone – Life Science Ventures and Technology Ventures – in the future will operate under the names Sunstone Life Science Ventures (https://sunstone.eu) and Heartcore Capital, respectively.
See also separate announcement from Heartcore Capital(https://medium.com/@heartcorecap/introducing-heartcore-capital-europes-consumer-only-vc-341341915409).
This is a natural further development of our activities and reflects the increased specialization of venture capital investment within the two sectors – ICT and Life Science. This calls for sharpening of the profiles and investment strategiesof the two investment arms, which is best accomplished under different brand names.
This news release follows the recent announcements of first closing of Sunstone Life Science Ventures Fund IV (“Sunstone LSV IV”) at €80 million and a further expansion of the investment team. The investment strategy of the new fund is a continuation of SunstoneLife Science Ventures’successful strategy of investing in novel therapeutics with the potential to improve the quality of patient careand treatment.
The Sunstone Life Science Ventures investment team consists of Søren Lemonius, Managing General Partner; Peter Benson, Chairman &General Partner; Dr Sten Verland, General Partner and Dr Claus Andersson, General Partnerwith the recent addition of Dr Jacob Lange Moresco, Investment Director. All experienced venture capital professionals with previous industry backgroundandaccess to an extensive network of industry experts and scientific leaders.
About SunstoneLife Science Ventures:
Sunstone Life Science Venturesis an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Life Science Venturesfocuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventureshas invested in more than 40companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOsand large M&A transactions. Managing total funds of approx. €500million, Sunstone Life Science Venturesis one of the largest European venture capital investors.
Sunstone contacts: Søren LemoniusManaging General Partner+45 40 81 48 89 email@example.com
Peter Benson Chairman & General Partner+45 40 80 48 69 firstname.lastname@example.org
Sten Verland, PhD MScGeneral Partner+45 24 22 19 69 email@example.com
Claus Andersson, PhDGeneralPartner+45 22 70 50 65 firstname.lastname@example.org
Sunstone Life Science VenturesA/S-Lautrupsgade 7, 2-DK-2100 Copenhagen, Denmarkhttp://sunstone.eu
Further Information, Logo: https://sunstone.eu/